Prevention of Post-traumatic Seizures With Levetiracetam

Phase 3

Terminated

• Conditions: Epilepsy, Post-Traumatic
• Interventions: Drug: Levetiracetam; Drug: Placebo

• Registration Number: NCT00566046
• Lead Sponsor: Rennes University Hospital

Brief Summary

Post-traumatic seizures can appear frequently after a severe traumatic brain injury. Two types of seizures are usually identified: early seizures during the week following the trauma and late epilepsy afterward. Several antiepileptic drugs are usually used to prevent early seizures but no treatment has demonstrated any preventive effect against late epilepsy. Levetiracetam is an antiepileptic drug usually used for the treatment of epileptic patients and has pharmacologic properties that could also be interesting for the prevention of post-traumatic epilepsy.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-11
• Study First Submitted: 2007-11-29
• Study First Submitted QC: 2007-11-29
• Study First Posted: 2007-11-30
• Primary Completion: 2009-12
• Study Completion: 2010-05
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-20
• Last Update Posted: 2012-06-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

1. Age >= 18 years old

2. Patient with severe brain injury defined as follow:

   • Initial Glasgow Coma score (assessed on the scene of the accident) <= 8 related to the brain injury
   • Stage 2 to 4 on the TDM US TCDB classification

3. Initial brain CT scan performed within 48 hours after hospital admission

4. Either a male or a nonpregnant, non-lactating female who is using adequate contraceptive method (a urine laboratory pregnancy test must be negative at baseline)

5. Written informed consent from the patient's next-of-kin. If no relative is present as the time of inclusion, the patients will be included according to the emergency procedure

Exclusion Criteria

1. Isolated extradural hematoma
2. Medical decision to limit patient's care (terminal stage of a cancer, hematological malignancies, HIV, etc.)
3. Current participation in an other protocol or within one month before study entry
4. Previous treatment with Levetiracetam
5. Patient's follow-up judged to be difficult by the investigator
6. Known allergy to either Levetiracetam or products derived from pyrrolidone or one of its excipients
7. Epileptic patient treated or not (except patients treated with benzodiazepines who can be included in this protocol)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Levetiracetam	Levetiracetam	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Time to early epileptic seizures (<= 8 days) and late epilepsy (from day 9 to 1 year) in patients with severe traumatic brain injury	one year

Secondary Outcome Measures

Name	Time	Method
Rate of early seizures and of late epilepsy; treatment effects according to the patient's severity, the TDM US Traumatic Coma Data Bank, and the number of regions traumatized; safety of Levetiracetam	One year
Global prognosis (Glasgow Outcome Scale)	3 months, 6 months and 1 year

Trial Locations

Locations (15)

Explorations Fonctionnelles Neurologiques - CHU Nantes; 🇫🇷 Rennes, France

Neurophysiologie Clinique - CHU Lille; 🇫🇷 Lille, France

Neurology - CHU Bordeaux; 🇫🇷 Bordeaux, France

Neurochirurgie-CHU Grenoble; 🇫🇷 Grenoble, France

Beurophysiologie clinique - CHU Marseille; 🇫🇷 Marseille, France

Neurologie - CHU Rouen; 🇫🇷 Rouen, France

Neurophysiologie clinique - CHU Lyon (Hôpital neurologique); 🇫🇷 Lyon, France

Neurologie - CHU Nancy; 🇫🇷 Nancy, France

Neurologie - CHU Angers; 🇫🇷 Angers, France

Neurologie - CHU Caen; 🇫🇷 Caen, France

Epileptologie - CHU Montpellier; 🇫🇷 Montpellier, France

Neurology - CHU Rennes; 🇫🇷 Grenoble, France

Neurochirurgie-Paris Saint Anne; 🇫🇷 Paris, France

Neurologie - CHU Tours Hopital Trousseau; 🇫🇷 Tours, France

Neurologie - CHU Rennes; 🇫🇷 Rennes, France